Anzeige
Mehr »
Login
Mittwoch, 19.03.2025 Börsentäglich über 12.000 News von 691 internationalen Medien
Vergessen Sie ChatGPT - Pioneer AIs DeepSeek R1 setzt neue Maßstäbe für sichere KI-Integration
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CTL4 | ISIN: CA05455W1086 | Ticker-Symbol: 954
Lang & Schwarz
19.03.25
10:12 Uhr
0,074 Euro
-0,074
-100,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
AWAKN LIFE SCIENCES CORP Chart 1 Jahr
5-Tage-Chart
AWAKN LIFE SCIENCES CORP 5-Tage-Chart
RealtimeGeldBriefZeit
0,0520,09510:12

Aktuelle News zur AWAKN LIFE SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.02.Awakn Life Sciences Corp.: Awakn Life Sciences Enters into Arrangement Agreement for The Acquisition of Awakn by Solvonis Therapeutics plc278Toronto, Ontario--(Newsfile Corp. - February 27, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing...
► Artikel lesen
24.02.Solvonis to buy Awakn Life Sciences for around £5 million4
24.02.Solvonis Therapeutic - Entry into an Arrangement Agreement with Awakn1
27.01.Awakn Life Sciences Corp.: Awakn Life Sciences Provides Update on R&D Programs, Progressing Novel Therapeutics for Alcohol Use Disorder and PTSD225Toronto, Ontario--(Newsfile Corp. - January 27, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company focused...
► Artikel lesen
27.01.Solvonis Therapeutic - Update on Awakn Life Sciences' R&D Progress6
21.01.Solvonis Therapeutic - Update on FDA Pre-IND Meeting for Awakn5
21.01.Awakn Life Sciences Corp: Awakn requires no more data before AWKN-002 phase 2b2
20.01.Awakn Life Sciences Corp.: Awakn Announces Positive Outcome of Pre-IND Meeting with FDA for AWKN-002 in Alcohol Use Disorder503Toronto, Ontario--(Newsfile Corp. - January 20, 2025) - Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing...
► Artikel lesen
AWAKN LIFE SCIENCES Aktie jetzt für 0€ handeln
18.12.24Awakn Life Sciences Corp: Awakn secures credit facility for up to $535,000 (U.S.)2
18.12.24Awakn Life Sciences Corp.: Awakn Life Sciences Announces Credit Facility376Toronto, Ontario--(Newsfile Corp. - December 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing...
► Artikel lesen
17.12.24Awakn Life Sciences Corp: Awakn enters LOI for acquisition by Graft Polymer for shares5
16.12.24XFRA 954: AUSSETZUNG/SUSPENSION264DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAWAKN LIFE SCIENCES...
► Artikel lesen
16.12.24Awakn Life Sciences Corp.: Awakn Life Sciences Enters into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) Plc437Toronto, Ontario--(Newsfile Corp. - December 16, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing...
► Artikel lesen
16.12.24Graft Polymer to buy Awakn in £4.98m deal3
16.12.24Graft Polymer (UK) - Proposed acquisition of Awakn Life Sciences Corp2
10.12.24Awakn Life Sciences Corp.: Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program567Toronto, Ontario--(Newsfile Corp. - December 10, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing...
► Artikel lesen
22.10.24Awakn Life Sciences Corp: Awakn Life opens four AWKN-001 clinical trial sites2
22.10.24Awakn Life Sciences Corp.: Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites383Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing...
► Artikel lesen
15.10.24Awakn Life Sciences Corp: Awakn Life to research aminoindane with Nottingham2
15.10.24Awakn Partners With University Of Nottingham For Preclinical Testing Of Psychoactive Therapy1
Seite:  Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1